Back in early April 2012, in a special report for Private Briefing readers called "The Biotech Buyout Binge," I explained that we would start seeing a slew of takeovers – engineered by cash-rich biopharmaceutical firms desperate to replace blockbusters that were losing patent protection.
We were right about the so-called "patent cliff."